JP2017531687A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531687A5
JP2017531687A5 JP2017522502A JP2017522502A JP2017531687A5 JP 2017531687 A5 JP2017531687 A5 JP 2017531687A5 JP 2017522502 A JP2017522502 A JP 2017522502A JP 2017522502 A JP2017522502 A JP 2017522502A JP 2017531687 A5 JP2017531687 A5 JP 2017531687A5
Authority
JP
Japan
Prior art keywords
cells
population
modified human
modified
immune system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017522502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531687A (ja
JP7005346B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/057652 external-priority patent/WO2016069647A1/en
Publication of JP2017531687A publication Critical patent/JP2017531687A/ja
Publication of JP2017531687A5 publication Critical patent/JP2017531687A5/ja
Application granted granted Critical
Publication of JP7005346B2 publication Critical patent/JP7005346B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017522502A 2014-10-27 2015-10-27 養子細胞免疫療法の有効性を増強させるための組成物および方法 Active JP7005346B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462069168P 2014-10-27 2014-10-27
US62/069,168 2014-10-27
PCT/US2015/057652 WO2016069647A1 (en) 2014-10-27 2015-10-27 Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy

Publications (3)

Publication Number Publication Date
JP2017531687A JP2017531687A (ja) 2017-10-26
JP2017531687A5 true JP2017531687A5 (cg-RX-API-DMAC7.html) 2018-12-06
JP7005346B2 JP7005346B2 (ja) 2022-02-04

Family

ID=54545485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017522502A Active JP7005346B2 (ja) 2014-10-27 2015-10-27 養子細胞免疫療法の有効性を増強させるための組成物および方法

Country Status (14)

Country Link
US (1) US10828352B2 (cg-RX-API-DMAC7.html)
EP (1) EP3212223B1 (cg-RX-API-DMAC7.html)
JP (1) JP7005346B2 (cg-RX-API-DMAC7.html)
KR (1) KR102357004B1 (cg-RX-API-DMAC7.html)
CN (1) CN107106611B (cg-RX-API-DMAC7.html)
AU (1) AU2015339402B2 (cg-RX-API-DMAC7.html)
BR (2) BR112017008710A8 (cg-RX-API-DMAC7.html)
CA (1) CA2965347C (cg-RX-API-DMAC7.html)
ES (1) ES2897731T3 (cg-RX-API-DMAC7.html)
HK (1) HK1243631A1 (cg-RX-API-DMAC7.html)
MX (1) MX389823B (cg-RX-API-DMAC7.html)
NZ (1) NZ731279A (cg-RX-API-DMAC7.html)
RU (1) RU2716716C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016069647A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351226B (es) 2011-09-08 2017-10-05 Yeda Res & Dev Celulas t con memoria central anti tercera parte, metodos para producirlas y uso de las mismas en transplante y tratamiento de enfermedades.
EP3563872A1 (en) 2012-04-05 2019-11-06 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
NZ739448A (en) 2014-04-10 2019-10-25 Seattle Children’S Hospital Dba Seattle Children’S Res Institute Transgene genetic tags and methods of use
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2017009852A1 (en) 2015-07-16 2017-01-19 Yeda Research And Development Co. Ltd. Use of anti third party central memory t cells
RU2018106515A (ru) 2015-07-21 2019-08-21 Зе Чилдрен'С Медикал Сентер Корпорейшн Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения
WO2017027291A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
AU2016345681A1 (en) 2015-10-30 2018-05-10 Nbe-Therapeutics Ag Anti-ROR1 antibodies
UA125718C2 (uk) 2016-01-20 2022-05-25 Зе Скріппс Ресеарч Інстітьют Композиції антитіл до ror1 і пов'язані з ними способи
AU2017213844A1 (en) 2016-02-02 2018-08-02 Fred Hutchinson Cancer Center Anti-ROR1 antibodies and uses thereof
EP3452082A1 (en) 2016-05-04 2019-03-13 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
JP7194022B2 (ja) * 2016-05-20 2022-12-21 イーライ リリー アンド カンパニー Notch阻害剤とPD-1またはPD-L1阻害剤との併用療法
CN106199005B (zh) * 2016-07-26 2019-02-01 浙江大学 采用cd137表达量检测淋巴细胞抗大肠癌活性的方法
EP4279136A3 (en) 2016-12-03 2024-03-20 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
MX2019006438A (es) 2016-12-05 2019-11-28 Juno Therapeutics Inc Produccion de celulas modificadas para terapia de celulas adoptivas.
EP3571295A1 (en) * 2017-01-18 2019-11-27 Yeda Research and Development Co. Ltd Genetically modified veto cells and use of same in immunotherapy
CN107267555B (zh) * 2017-05-27 2020-03-20 上海优卡迪生物医药科技有限公司 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用
KR102486090B1 (ko) 2017-08-07 2023-01-10 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
WO2019033057A1 (en) * 2017-08-11 2019-02-14 Fred Hutchinson Cancer Research Center SPECIFIC BRAF TCR AND USES THEREOF
KR20200055037A (ko) * 2017-09-19 2020-05-20 메사추세츠 인스티튜트 오브 테크놀로지 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
AU2018339528A1 (en) * 2017-09-26 2020-04-16 Longwood University PD1-specific chimeric antigen receptor as an immunotherapy
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
CA3082334A1 (en) * 2017-11-20 2019-05-23 Julius-Maximilians-Universitat Wurzburg Cd19cart cells eliminate myeloma cells that express very low levels of cd19
US20210198372A1 (en) 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
CN109810995B (zh) * 2017-12-06 2020-10-02 阿思科力(苏州)生物科技有限公司 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用
CN108148137B (zh) * 2017-12-29 2021-03-23 中国人民解放军第四军医大学 一种b7h4/1e10单克隆抗体及其应用
BR112021003830A2 (pt) * 2018-08-28 2021-07-20 Fred Hutchinson Cancer Research Center métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida
CN111544585B (zh) * 2019-02-11 2024-12-27 北京卡替医疗技术有限公司 一种可助推免疫细胞在体内扩增的佐剂
WO2020191305A2 (en) 2019-03-20 2020-09-24 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
EP3983539A1 (en) * 2019-06-14 2022-04-20 Flagship Pioneering Innovations VI, LLC Circular rnas for cellular therapy
WO2021129927A1 (en) * 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
AU2021297458A1 (en) * 2020-06-25 2023-02-02 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
US20050129671A1 (en) * 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
JP2008527001A (ja) 2005-01-13 2008-07-24 ザ ジョンズ ホプキンス ユニバーシティー 前立腺幹細胞抗原ワクチンおよびその使用
US20090324630A1 (en) * 2008-04-21 2009-12-31 Jensen Michael C Fusion multiviral chimeric antigen
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
BR112013024395B1 (pt) * 2011-03-23 2021-10-26 Fred Hutchinson Cancer Research Center Composições adotivas de imunoterapia celular e método para fabricação da dita composição
KR102028340B1 (ko) * 2011-04-13 2019-10-04 이뮤니쿰 에이비 항원-특이적 t 세포의 증식 방법
JP6117515B2 (ja) * 2011-11-01 2017-04-19 国立大学法人名古屋大学 髄膜腫治療用医薬組成物
EP3811954A1 (en) * 2013-02-26 2021-04-28 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells

Similar Documents

Publication Publication Date Title
JP2017531687A5 (cg-RX-API-DMAC7.html)
RU2017114174A (ru) Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии
Johdi et al. Colorectal cancer immunotherapy: options and strategies
Baxevanis et al. Cancer immunotherapy
Kiesgen et al. Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies
JP7487112B2 (ja) Cd19指向性キメラ抗原受容体および免疫療法におけるその使用
Kershaw et al. Gene-engineered T cells for cancer therapy
Wang et al. Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
Dai et al. Chimeric antigen receptors modified T-cells for cancer therapy
Li et al. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
Essand et al. Genetically engineered T cells for the treatment of cancer
Chang et al. Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells
Spear et al. Strategies to genetically engineer T cells for cancer immunotherapy
JP2022535429A (ja) 免疫療法のための操作されたナチュラルキラー細胞と操作されたt細胞の組み合わせ
JP2020509767A5 (cg-RX-API-DMAC7.html)
JP7717686B2 (ja) キメラcd3融合タンパク質と抗cd3ベースの二重特異性t細胞活性化エレメントの複合発現
CN111787938A (zh) 靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法
JP2015527070A5 (cg-RX-API-DMAC7.html)
IL314563A (en) Non-HLA-restricted T-cell receptors and their uses
CN111247241A (zh) T细胞受体缺陷型嵌合抗原受体t细胞和其使用方法
WO2012079000A4 (en) Use of chimeric antigen receptor-modified t cells to treat cancer
CN108410892A (zh) 降低由pd-l1诱导的免疫耐受性
WO2018210279A1 (zh) Toll样受体激动剂与免疫效应细胞的联用
JPWO2019157454A5 (cg-RX-API-DMAC7.html)
Danhof et al. CARs and other T cell therapies for MM: the clinical experience